Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint

As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-Lung06 demonstrated the superiority of replacing conventional pemetrexed/platinum chemotherapy with sac-TMT, with significantly prolonged...

United Kingdom Digital Health Market Size to Reach USD 43.98 Billion by 2031, Driven by NHS Digitalization

BrightSpring Health Services Set to Join S&P MidCap 400 and Karman Holdings to Join S&P SmallCap 600

NEW YORK, July 14, 2026 /PRNewswire/ -- S&P SmallCap 600 constituent BrightSpring Health Services Inc. (NASD: BTSG) will replace Chart Industries Inc. (NYSE: GTLS) in the S&P MidCap 400, and Karman Holdings Inc. (NYSE: KRMN) will replace BrightSpring Health Services in the S&P SmallCap...

AI Search Engineers Reports That Professional Service Businesses Using ...

(PR-inside.com) The No. 1 AI certified agency and only AEO Verified agency in the United States releases comparative data showing that the integrated deployment of AI chatbots and Answer Engine Optimization produces three times more qualified leads for law firms, financial advisors, and medical practices than either system deployed independently. AMHERST, NY / ACCESS Newswire / July 14, 2026 / AI Search Engineers, the #1 AI certified agency and the only AEO Verified agency in the United States meeting all Tier 1 requirements under the AEO Differentiation Standard, today released comparative data documenting that professional service businesses deploying AI chatbots alongside Answer ..

AI Search Engineers Reports That Professional Service Businesses Using AI Chatbots Alongside Answer Engine Optimization See 3X More Qualified Leads Than Businesses Using Either System Alone

The No. 1 AI certified agency and only AEO Verified agency in the United States releases comparative data showing that the integrated deployment of AI chatbots and Answer Engine Optimization produces three times more qualified leads for law firms, financial advisors, and medical practices than either system deployed independently.

Cora Launches First Commercial, Raising the Standards for a New Generation

The clean period care brand launches its Back to School campaign, reimagining period care for Gen Z and Gen Alpha. NEW YORK, July 14, 2026 /PRNewswire/ -- For millions of people, health class was the introduction to period care and the message was clear: discomfort was just part of the...

Cardiovascular Logistics Names Dr. Gary Kirsh Chief Executive Officer

Veteran physician executive and former Solaris Health CEO to lead one of the nation's largest cardiology platforms NASHVILLE, Tenn., July 14, 2026 /PRNewswire/ -- Cardiovascular Logistics ("CVL" or the "Company"), one of the nation's leading cardiology management services organizations,...

Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer

MINNEAPOLIS, July 14, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced that the U.S. Food and Drug Administration (“FDA”) approved REVTORPYK™ (gedatolisib) for the treatment of patients with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. REVTORPYK is the only inhibitor of class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2 to receive FDA approval.

Public Health Groups, Pediatricians and Parents Sue FDA Over Policy Allowing the Marketing of Unauthorized E-Cigarettes and Nicotine Pouches

WASHINGTON, July 14, 2026 /PRNewswire/ -- A coalition of public health organizations, pediatricians and parents today filed a federal lawsuit challenging the Food and Drug Administration's new enforcement policy that allows e-cigarette and nicotine pouch products to be marketed and sold...

Jack and Jill of America Opens Its Doors: 47th National Convention Brings Baltimore a Town Hall with Laura Coates and a Free Community Health & Resource Fair

National convening will connect families, uplift Baltimore leaders and strengthen pathways for the next generation through two free public events WASHINGTON, July 14, 2026 /PRNewswire/ -- Thousands of families will arrive in Baltimore from July 21–26 as Jack and Jill of America,...

Formycon AG and OneSource Specialty Pharma Announce Strategic Manufacturing Partnership for Biosimilars

MUNICH, GERMANY and BANGALORE, INDIA - July 14, 2026 ( NEWMEDIAWIRE ) - Formycon AG (FSE: FYB, Prime Standard, “Formycon”) and OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE, “OneSource”), a multi-modality specialty pharma CDMO, today announced a strategic manufacturing partnership for biosimilars. Under the partnership, OneSource will serve as a strategic manufacturing partner for Formycon and provide integrated Drug Substance (DS) and Drug Product (DP) manufacturing capabilities from its state-of-the-art biologics’ facility in Bangalore, India. The collaboration brings together Formycon’s biosimilar development excellence with OneSource’s end-to-end biologics manufacturing expertise to support Formycon’s biosimilar programs for global markets. Dr. Stefan Glombitza, Chief

Chris Long Named President of Micross North America

MELVILLE, N.Y., July 14, 2026 /PRNewswire/ -- Micross Components, Inc. ("Micross" or the "Company"), a global provider of high-reliability microelectronic products and services for aerospace, defense, space, medical, and industrial applications, and a portfolio company of Behrman Capital,...